个体化静脉溶栓治疗的研究进展  

Research Progress of Individualized Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator

作　　者：赵秋云[1] 丁红[2] 徐运[1] 

机构地区：[1]南京大学医学院附属鼓楼医院神经科,南京1210008 [2]南京医科大学第二附属医院神经科

出　　处：《中国卒中杂志》2014年第4期294-302,共9页Chinese Journal of Stroke

摘　　要：缺血性卒中严重影响着人类的生活。静脉重组组织型纤溶酶原激活剂(intravenous recombinant tissue plasminogen activator,rt-PA)溶栓治疗是目前被循证医学证明缺血性卒中急性期唯一有效的方法。然而,在临床实施中,存在一些问题,如时间窗问题、伴随意识障碍问题、年龄问题、剂量问题等等,提示在规范的基础上需进行个体化治疗,从而提高溶栓的有效性和安全性。本文就静脉溶栓中涉及个体化方案临床研究的最新进展做一综述。Ischemic stroke has a serious impact on human life. It has been proven that intravenous thrombolysis with recombinant tissue plasminogen activator （rt-PA） is currently the only effective therapy for acute ischemic stroke by evidence-based medicine. However, some questions appear when doctors make prescription, such as narrow time window, with decreased level of consciousness, age, dosage of rt-PA. It suggests that individual therapy should be taken based on standard guide that could increase the efficacy and safety on the thrombolysis. Here, we review the latest developments of intravenous thrombolysis involving individualized clinical studies.

关 键 词：静脉溶栓 卒中 个体化 

分 类 号：R743.3[医药卫生—神经病学与精神病学]